BlackRock Amends Haemonetics Stake, Passive Investment Update
Ticker: HAE · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 313143
| Field | Detail |
|---|---|
| Company | Haemonetics Corp (HAE) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, amendment, medical-devices
TL;DR
**BlackRock updated its passive stake in Haemonetics; no major red flags, just routine disclosure.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, indicating a change in its ownership of Haemonetics Corp. as of December 31, 2023. This amendment, number 17, shows BlackRock's updated passive investment stake in the medical instruments company. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in its confidence or strategy regarding Haemonetics stock.
Why It Matters
This filing updates BlackRock's passive ownership in Haemonetics, providing transparency on a significant institutional investor's position, which can influence market perception.
Risk Assessment
Risk Level: low — This is a routine amendment by a passive institutional investor, indicating no immediate high-risk events for the stock.
Analyst Insight
Investors should note BlackRock's continued passive interest in Haemonetics, but this filing alone doesn't suggest a need for immediate action; it's a routine disclosure of a large institutional holding.
Key Numbers
- 17 — Amendment Number (This is the 17th amendment to BlackRock's Schedule 13G filing for Haemonetics Corp., indicating ongoing adjustments to its reported ownership.)
- 405024100 — CUSIP Number (This unique identifier confirms the specific class of securities (Common Stock) of Haemonetics Corp. being reported.)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Haemonetics Corp. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A amendment
Forward-Looking Statements
- BlackRock will continue to hold a significant, passive stake in Haemonetics Corp. (BlackRock Inc.) — high confidence, target: Q2 2024
FAQ
What type of filing is this and what does it generally indicate?
This is an SC 13G/A filing, which is an amendment to a Schedule 13G. It generally indicates that a passive institutional investor, like BlackRock Inc., has updated its ownership stake in a company, in this case, Haemonetics Corp., and is not seeking to influence management.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a major institutional investment manager based out of 50 Hudson Yards, New York, NY.
What is the subject company whose shares are being reported?
The subject company is HAEMONETICS CORP, a company in the Surgical & Medical Instruments & Apparatus industry, located at 125 Summer Street, Boston, MA.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, meaning the reported ownership figures reflect BlackRock's position as of that date.
Which rule under the Securities Exchange Act of 1934 is designated for this filing?
This Schedule 13G is filed under Rule 13d-1(b), which is typically used by passive institutional investors who own more than 5% but less than 20% of a company's stock and do not intend to influence control.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding HAEMONETICS CORP (HAE).